Vincristine Sulfate (CAS 2068-78-2)

5.0(2)

Escrever uma revisão de produto Pergunte

Veja citações de produtos (14)

Nomes alternativos: VCR . sulfate;Leukocristine . sulfate

Aplicação Vincristine Sulfate is a cell cycle arresting, apoptotic inducing alkaloid

Numero VAT: 2068-78-2

Privada: ≥98%

Peso Molecular: 923.04

Separar por Funcao: C₄₆H₅₆N₄O₁₀•H₂SO₄

Informação complementar: This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.

Para uso em exclusivo em pesquisa. Não se destina a uso em diagnostico e tratamento.

* Refere-se a Certificado de Análise para data especifica de lotes (incluindo-se o conteúdo de agua).

LINKS RÁPIDOS

caspase-3 (31A1067): sc-56053. Western blot analysis of cleaved caspase-3...

Clique na imagem ou no botão para ampliar a imagem

Vincristine Sulfate, a dimeric Vinca alkaloid, has been shown to bind to Tubulin via a protein self association reaction. This compound acts as a Tubuiln inhibitor by binding to sites at the ends of microtubules, which regulate the inhibition of Tubulin dimer addition to microtubule ends. Experiments have reported Vincristine Sulfate to demonstrate a capacity to suppress growth of proliferating cells through marked apoptosis and cell cycle arrest at G2/M. The cell death caused by this agent seems to result in a sustained accumulation of endogenous ceramide levels. Ceramide, has been proposed as a lipid second messenger with specific antiproliferative mediating responses. Vincristine Sulfate is an inhibitor of MAO. Vincristine Sulfate is also a substrate of PGP and CYP3A4.

Referencias

The morphological effects of vincristine sulfate on canine bone marrow cells. | Alleman, AR. and Harvey, JW. 1993. Vet Clin Pathol. 22: 36-41. PMID: 12669276
Binding selectivity of rhizoxin, phomopsin A, vinblastine, and ansamitocin P-3 to fungal tubulins: differential interactions of these antimitotic agents with brain and fungal tubulins. | Li, Y., et al. 1992. Biochem Biophys Res Commun. 187: 722-9. PMID: 1530630
Vincristine sulfate as a possible cause of optic neuropathy. | Weisfeld-Adams, JD., et al. 2007. Pediatr Blood Cancer. 48: 238-40. PMID: 16206187
Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules. | Himes, RH. 1991. Pharmacol Ther. 51: 257-67. PMID: 1784631
PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. | Song, X., et al. 2008. Int J Pharm. 350: 320-9. PMID: 17913411
Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. | Ling, G., et al. 2010. J Control Release. 148: 241-8. PMID: 20727928
Folic acid and cell-penetrating peptide conjugated PLGA-PEG bifunctional nanoparticles for vincristine sulfate delivery. | Chen, J., et al. 2012. Eur J Pharm Sci. 47: 430-43. PMID: 22796217
Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. | Silverman, JA. and Deitcher, SR. 2013. Cancer Chemother Pharmacol. 71: 555-64. PMID: 23212117
Multifunctional nanoparticles as nanocarrier for vincristine sulfate delivery to overcome tumor multidrug resistance. | Wang, Y., et al. 2014. Mol Pharm. 11: 885-94. PMID: 24483832
Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT). | Hantrakul, S., et al. 2014. J Vet Med Sci. 76: 1549-53. PMID: 25649934
Conventional-Vincristine Sulfate vs. Modified Protocol of Vincristine Sulfate and L-Asparaginase in Canine Transmissible Venereal Tumor. | Setthawongsin, C., et al. 2019. Front Vet Sci. 6: 300. PMID: 31620453
Pharmacokinetics of vincristine sulfate in adult cancer patients. | Sethi, VS., et al. 1981. Cancer Res. 41: 3551-5. PMID: 7260915
Pharmacokinetics of vincristine sulfate in children. | Sethi, VS. and Kimball, JC. 1981. Cancer Chemother Pharmacol. 6: 111-5. PMID: 7307229
Bcl-2 interrupts the ceramide-mediated pathway of cell death. | Zhang, J., et al. 1996. Proc Natl Acad Sci U S A. 93: 5325-8. PMID: 8643573
Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. | Embree, L., et al. 1998. Cancer Chemother Pharmacol. 41: 347-52. PMID: 9523729

Aparência :

Powder

Estado físico :

Solid

envie :

Soluble in water (25 mg/ml), ethanol, and methanol.

Manutencao :

Store at -20° C

Ponto de fusão :

300° C

Ponto de fervura :

273-281° C

IC50 :

OVCAR-3 : IC₅₀ = 10 nM (human); PC-3: IC₅₀ = 11 nM (human); LNCaP: IC₅₀ = 2.9 nM (human)

Valores de pK :

pK_a: 11.10

Para uso em exclusivo em pesquisa. Não se destina a uso em diagnostico e tratamento.

WGK Alemanha :

RTECS :

OH6340000

PubChem CID :

5388992

Indice de produtos :

14: 9986

Numero de FAX :

MFCD00084729

Numero de FAX :

218-190-0

Registro Beilstein :

3924631

SMILES :

CC[[email protected]@]1(C[[email protected]]2C[[email protected]@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[[email protected]]78CCN9[[email protected]]7[[email protected]@](C=CC9)([[email protected]]([[email protected]@]([[email protected]@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O

Baixar SDS (MSDS)

Region

SAMPLE Certificate of Analysis (COA)

Vincristine Sulfate | CAS 2068-78-2 SAMPLE Certificate of Analysis

Certificado de Análise

SAMPLE Certificate of Analysis (COA)

Catalog Number:sc-201434

Lot Number:SAMPLE

Product Name:Vincristine Sulfate

Molecular Formula:C₄₆H₅₆N₄O₁₀•H₂SO₄

Molecular Weight:923.0

Test	Specification	Results
Appearance	White to off-white solid	White solid
Microanalysis	Elemental analysis within 0.4 of expected result for each element tested	Complies
Identification (¹H-NMR)	Consistent with structure and shows < 1% of any other impurity	Complies
Identification (Mass Spectrometry)	Electrospray positive shows mass ion corresponding to [M-H2SO4+H]+ and [M-H2SO4+2H]2+	Mass ions: 825.5 and 413.5
Purity (HPLC)	> 98% by RP analysis	Complies
TLC	Single spot	Rf = 0.50
Solubility	Soluble in water to 100 mM	Complies